Independent scientists and doctors support FDA approval of first drug to slow disease progression. Lecanemab is not without controversy because of its side effects, such as brain hemorrhages and brain inflammation.
The FDA must decide whether to definitively approve the drug, which would be indicated for people with early Alzheimer's. The committee recommended genetic testing of patients before they take the drug to determine if they have that mutation. They have also recommended excluding people who take blood thinners, or informing them of the risk they run.